The company had already announced plans to treat Bayer CropScience as a separate unit.
It still appears that Bayer may buy Aventis CropScience, the agricultural division of Franco-German drug giant Aventis .
Bayer failed to strike a juror in the previous MDL trial who was a Greenpeace contributor.
However, some think Pfizer might have an edge because Bayer's drug shrank tumors by only 2%.
Bayer chemists developed Nexavar based on proteins Onyx identified that showed promise for halting tumor growth.
Diadexus must work fast because Millennium, Abbott and Bayer are also hot on the trail.
This could cut into sales for Onyx Pharmaceuticals and Bayer 's Nexavar drug for kidney cancer.
Expect Bayer, which sells Aleve, to run more ads touting the drug's heart-safe status.
That deal failed, as another German drug firm, Bayer of Leverkeusen, merged with Schering.
Its lead drug to treat chemotherapy side effects failed, and the Bayer deal yielded nothing fast.
Bayer's Werner Wenning has yet to find a partner for the company's ailing drug division.
Meanwhile, however, Bayer's sturdy crop and chemical businesses, slow and steady, continue to soldier on.
But chemical firm Bayer told the committee their assessment was riddled with "knowledge gaps".
Bayer Schering would rank among the top 12 health care firms in the world.
Unfortunately, the good data is not enough to firm up Bayer's limping drug division.
India's patent appeal board in March rejected Bayer's attempts to get the decision overturned.
Bayer stock hasn't budged in a year and is valued at 17 times earnings.
The purchase of Aventis CropScience makes Bayer's agriculture division one of the biggest in the world.
Bayer has tried to fill gaps in its drug pipeline by partnering with biotechnology companies.
Bayer insists it won't sell, but hopes to partner the unit off early next year.
Sandra Peterson of Bayer, a German drugs and devices giant, stoutly defends the industry's record.
Bayer trades 32% below its break-up value, only 21 times Julius Baer's estimate of 2001 earnings.
Bayer has already been approached by potential bidders, rumored to include Aventis, Roche, GlaxoSmithKline and Novartis.
But a momentary bump, no matter how significant, does not begin to address Bayer's larger problems.
Bayer has resolutely said there will be no such sale, but it is open to partnership.
In December 1999, Bayer changed the labeling on Baycol to warn of the Lopid drug interaction.
But Bayer's warnings to doctors not to give the two drugs together may have gone unheeded.
Bayer has assured both governments that it can meet demand, saying it has a million-pill stockpile.
One similar medication, Bayer's Baycol, was taken off the market due to lethal side effects.
That's probably why Bayer stock is up more than 2% on the Frankfurt exchange.
应用推荐